{"title":"[Migraine headaches: What is new in treatment?]","authors":"María Celeste Buompadre","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Migraine is the most common acute and recurrent headache disorder in the pediatric population. Its management is typically divided into acute and preventive interventions. This article aims to review the current evidence for both therapeutic approaches in migraine, with a focus on emerging treatment options approved for adult use, and currently under investigation in children and adolescents. Both pharmacological and nonpharmacological strategies under study are discussed, including onabotulinumtoxinA, neuromodulation devices, gepants, monoclonal antibodies, and 5-hydroxytryptamine receptor agonists. To date, topiramate and propranolol have shown modest benefits compared to placebo. Although the evidence supporting the use of novel therapies in pediatric migraine is expanding, it remains limited and under development.</p>","PeriodicalId":18419,"journal":{"name":"Medicina-buenos Aires","volume":"85 Suppl 4 ","pages":"71-76"},"PeriodicalIF":0.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina-buenos Aires","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Migraine is the most common acute and recurrent headache disorder in the pediatric population. Its management is typically divided into acute and preventive interventions. This article aims to review the current evidence for both therapeutic approaches in migraine, with a focus on emerging treatment options approved for adult use, and currently under investigation in children and adolescents. Both pharmacological and nonpharmacological strategies under study are discussed, including onabotulinumtoxinA, neuromodulation devices, gepants, monoclonal antibodies, and 5-hydroxytryptamine receptor agonists. To date, topiramate and propranolol have shown modest benefits compared to placebo. Although the evidence supporting the use of novel therapies in pediatric migraine is expanding, it remains limited and under development.